Goldman Sachs
STOK icon

Goldman Sachs’s Stoke Therapeutics STOK Stock Holding History

Goldman Sachs’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$27M Sell
830,702
-312,035
-27% -$10.2M ﹤0.01% 2152
2025
Q4 		$36.3M Sell
1,142,737
-8,192
-0.7% -$246K ﹤0.01% 1778
2025
Q3 		$27M Sell
1,150,929
-150,452
-12% -$2.58M ﹤0.01% 1961
2025
Q2 		$14.8M Sell
1,301,381
-360,658
-22% -$3.42M ﹤0.01% 2391
2025
Q1 		$11.1M Buy
1,662,039
+293,072
+21% +$2.73M ﹤0.01% 2606
2024
Q4 		$15.1M Sell
1,368,967
-24,793
-2% -$305K ﹤0.01% 2403
2024
Q3 		$17.1M Buy
1,393,760
+26,243
+2% +$372K ﹤0.01% 2204
2024
Q2 		$18.5M Sell
1,367,517
-36,538
-3% -$493K ﹤0.01% 1951
2024
Q1 		$19M Buy
1,404,055
+12,624
+0.9% +$76.5K ﹤0.01% 1885
2023
Q4 		$7.32M Buy
1,391,431
+1,262,126
+976% +$5.39M ﹤0.01% 2802
2023
Q3 		$509K Buy
129,305
+35,804
+38% +$235K ﹤0.01% 4651
2023
Q2 		$994K Buy
93,501
+11,329
+14% +$121K ﹤0.01% 4341
2023
Q1 		$684K Buy
82,172
+14,310
+21% +$129K ﹤0.01% 4642
2022
Q4 		$626K Sell
67,862
-44,404
-40% -$462K ﹤0.01% 4727
2022
Q3 		$1.44M Sell
112,266
-9,521
-8% -$152K ﹤0.01% 4242
2022
Q2 		$1.61M Buy
121,787
+7,745
+7% +$118K ﹤0.01% 4231
2022
Q1 		$2.4M Sell
114,042
-12,289
-10% -$246K ﹤0.01% 4098
2021
Q4 		$3.03M Sell
126,331
-46,418
-27% -$1.11M ﹤0.01% 3873
2021
Q3 		$4.39M Buy
172,749
+36,361
+27% +$1.01M ﹤0.01% 3470
2021
Q2 		$4.59M Sell
136,388
-421,985
-76% -$14.9M ﹤0.01% 3415
2021
Q1 		$21.7M Sell
558,373
-18,597
-3% -$1.06M 0.01% 1869
2020
Q4 		$35.7M Buy
576,970
+468,466
+432% +$21.5M 0.01% 1393
2020
Q3 		$3.63M Sell
108,504
-34,680
-24% -$990K ﹤0.01% 3135
2020
Q2 		$3.41M Buy
143,184
+122,228
+583% +$2.9M ﹤0.01% 3070
2020
Q1 		$480K Sell
20,956
-47,017
-69% -$1.16M ﹤0.01% 4244
2019
Q4 		$1.93M Buy
67,973
+21,786
+47% +$548K ﹤0.01% 3677
2019
Q3 		$993K Sell
46,187
-33,475
-42% -$933K ﹤0.01% 4039
2019
Q2 		$2.32M Buy
+79,662
New +$2.14M ﹤0.01% 3436

Other funds holding STOK

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Goldman Sachs's STOK Position: Q1 2026 in Review

Goldman Sachs reduced its Stoke Therapeutics (STOK) stake by 27% in Q1 2026, selling an estimated $10.2M and leaving 830,702 shares worth $27M. The position accounts for ﹤0.01% of the portfolio, ranked #2152.

Goldman Sachs first reported a position in STOK in Q2 2019 and has held it in 28 quarters since. The position peaked at $36.3M in Q4 2025. 196 funds tracked by Wall St. Rank hold STOK as of Q1 2026.

  • Goldman Sachs held 830,702 shares of Stoke Therapeutics worth $27M as of Q1 2026.
  • Goldman Sachs sold 312,035 Stoke Therapeutics shares in Q1 2026, an estimated $10.2M.
  • Stoke Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #2152 holding.
  • Goldman Sachs first reported a position in Stoke Therapeutics in Q2 2019 and has held it in 28 quarters since.
  • Goldman Sachs's Stoke Therapeutics position peaked at $36.3M in Q4 2025.
  • 196 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.